NIPH Clinical Trials Search

Study on the safety of hydrogen inhalation in hemodialysis patients.

Basic Information

Recruitment status	Recruiting
Health condition(s) or Problem(s) studied	Chronic kidney disease G5D (under hemodialysis)
Date of first enrollment	07/03/2025
Target sample size	10
Countries of recruitment
Study type	Interventional
Intervention(s)	Hydrogen inhalation (250 mL/min) for 24 weeks during haemodialysis (3 times a week for approx. 4 hr/treatment).

Outcome(s)

Primary Outcome	Safety (adverse events)
Secondary Outcome	Relationship between hydrogen dosage and hydrogen blood concentration, expiratory gas analysis and ABI/CAVI, effect on anemia, effect on fatigue

Key inclusion & exclusion criteria

Age minimum	>= 18age old
Age maximum	Not applicable
Gender	Both
Include criteria	(1) Patients who have been on maintenance haemodialysis (including haemodialysis and haemodiafiltration) for at least 3 months. (2) Patients who are at least 18 years of age at the time of consent . (3) Gender Not applicable. (4) Inpatient or outpatient Not applicable. (5) Patients who have been fully informed of the study and have given their voluntary written consent based on full understanding.
Exclude criteria	(1) Patients with a history of or complicated with malignant tumours. However, patients with a history of malignant tumours who are untreated and have not relapsed for more than 5 years at the time of obtaining consent may be included. (2) Patients complicated with unstable angina or non-compensated heart failure. (3) Patients complicated with cirrhosis or liver failure. (4) Patients who require oxygen inhalation during dialysis. (5) Patients with frequent hypotension during dialysis (6)Patients who are judged to be inappropriate as research subjects by the principal investigator (co-principal investigator).